Background: The party drug gamma hydroxybutyrate (GHB) is highly addictive. GHB use disorder (GUD) has poor treatment outcome, with relapse rates over 60% within 3 months after detoxification. In order to get a better understanding of the limited treatment success, we explored GUD patients’ illness perceptions and treatment needs. Methods: In a qualitative cross-sectional observational study, using a semi-structured interview based on the works of Kleinmann, illness perceptions were explored among treatment seeking GUD patients (n = 20). The analysis was based on the principles of Grounded Theory by the 2 interviewers and an independent researcher. Results: GUD patients had mainly positive views toward GHB. GHB was perceived as strongly rewarding and perceived as the solution to psychosocial problems, rather than the cause. After repeated readmissions, GUD patients perceived themselves as addicted to GHB and GHB use as more problematic. They reported a need for personalized treatment goals, which were mainly aimed toward dealing with psychiatric symptoms and social reintegration. Conclusion: GUD shares many characteristics with other substance use disorders, in line with gradual development from positive reinforcement in early-stage GUD to negative reinforcement in later stages of more compulsive GHB use. Future studies should investigate whether personalization of treatment goals, such as social reintegration, lead to better treatment outcomes.

Keywords:
Gamma hydroxybutyrate acid, Abuse and dependence, Qualitative research, Attitude, Addiction, Illness perception
1.
Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med. 2005 Jun;352(26):2721–32.
2.
Bosch OG, Eisenegger C, Gertsch J, von Rotz R, Dornbierer D, Gachet MS, et al. Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone. Psychoneuroendocrinology. 2015 Dec;62:1–10.
3.
Bosch OG, Havranek MM, Baumberger A, Preller KH, von Rotz R, Herdener M, et al. Neural underpinnings of prosexual effects induced by gamma-hydroxybutyrate in healthy male humans. Eur Neuropsychopharmacol. 2017 Apr;27(4):372–82.
4.
Kamal RM, van Noorden MS, Wannet W, Beurmanjer H, Dijkstra BA, Schellekens A. Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention. CNS Drugs. 2017 Jan;31(1):51–64.
5.
van Noorden M, Kamal R, Dijkstra B, Brunt TM, De Jong C. Gamma-Hydroxybutyrate Abuse and Dependence. In: Neuropathology of Drug Addictions and Substance Misuse. 2016, pp 379–387.
6.
Brunt TM, van Amsterdam JG, van den Brink W. GHB, GBL and 1,4-BD addiction. Curr Pharm Des. 2014;20(25):4076–85.
7.
Degenhardt L. GHB: un análisis. Adicciones. 2003;15(5):167–77.
8.
Busardò FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome. Eur Rev Med Pharmacol Sci. 2015 Dec;19(23):4654–63.
9.
Dijkstra BA, Kamal R, van Noorden MS, de Haan H, Loonen AJ, De Jong CA. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: the Dutch GHB monitor project. Drug Alcohol Depend. 2017 Jan;170:164–73.
10.
Sumnall HR, Woolfall K, Edwards S, Cole JC, Beynon CM. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend. 2008 Jan;92(1–3):286–90.
11.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2018: Trends and Developments. 2018.
12.
van Amsterdam J, Brunt T, Pennings E, van den Brink W. Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB. Regul Toxicol Pharmacol. 2014 Nov;70(2):507–13.
13.
de Weert-van Oene GH, Schellekens AF, Dijkstra BA, Kamal R, de Jong CA. [Detoxification of patients with GHB dependence]. Tijdschr Psychiatr. 2013;55(11):885–90.
14.
Miotto K, Roth B: GHB withdrawal syndrome. 2001.
15.
Degenhardt L, Darke S, Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend. 2002 Jun;67(1):89–94.
16.
Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend. 2009 Sep;104(1–2):1–10.
17.
Galloway GP, Frederick SL, Staggers FE Jr, Gonzales M, Stalcup SA, Smith DE. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction. 1997 Jan;92(1):89–96.
18.
Gonzalez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol. 2005 Mar;19(2):195–204.
19.
McDaniel CH, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs. 2001 Apr–Jun;33(2):143–9.
20.
van Noorden MS, van Dongen LC, Zitman FG, Vergouwen TA. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiatry. 2009 Jul-Aug;31(4):394–6.
21.
Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med. 2000 Jan;18(1):65–70.
22.
McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend. 2004 Jul;75(1):3–9.
23.
van Noorden MS, Mol T, Wisselink J, Kuijpers W, Dijkstra BA. Treatment consumption and treatment re-enrollment in GHB-dependent patients in The Netherlands. Drug Alcohol Depend. 2017 Jul;176:96–101.
24.
Mol T, Wisselink J, Kuijpers W, Dijkstra B. GHB: recidive op eenzame hoogte. Verslaving. 2014;10(3):69–79.
25.
Leventhal H, Meyer D, Nerenz D. The common sense model of illness danger. Med Psychol; 1980. pp. 7–30.
26.
Leventhal H, Phillips LA, Burns E. The Common-Sense Model of Self-Regulation (CSM): a dynamic framework for understanding illness self-management. J Behav Med. 2016 Dec;39(6):935–46.
27.
Moss-Morris R, Weinman J, Petrie K, Horne R, Cameron L, Buick D. The revised Illness Perception Questionnaire (IPQ-R). Psychol Health. 2002;17(1):1–16.
28.
Büchi S, Sensky T, Sharpe L, Timberlake N. Graphic representation of illness: a novel method of measuring patients’ perceptions of the impact of illness. Psychother Psychosom. 1998 Jul-Oct;67(4–5):222–5.
29.
Klis S, Vingerhoets AJ, de Wit M, Zandbelt N, Snoek FJ. Pictorial Representation of Illness and Self Measure Revised II (PRISM-RII): a novel method to assess perceived burden of illness in diabetes patients. Health Qual Life Outcomes. 2008 Nov;6(1):104.
30.
Groleau D, Young A, Kirmayer LJ. The McGill Illness Narrative Interview (MINI): an interview schedule to elicit meanings and modes of reasoning related to illness experience. Transcult Psychiatry. 2006 Dec;43(4):671–91.
31.
Hagger MS, Orbell S. A meta-analytic review of the common-sense model of illness representations. Psychol Health. 2003;18(2):141–84.
32.
Jones CJ, Smith HE, Llewellyn CD. A systematic review of the effectiveness of interventions using the Common Sense Self-Regulatory Model to improve adherence behaviours. J Health Psychol. 2016 Nov;21(11):2709–24.
33.
Chan RC, Mak WW. Common sense model of mental illness: understanding the impact of cognitive and emotional representations of mental illness on recovery through the mediation of self-stigma. Psychiatry Res. 2016 Dec;246:16–24.
34.
Kleinman A. What Kind of Model for the Anthropology of Medical Systems? Am Anthropol. 1978;80(3):661–5.
35.
Kleinman A, Eisenberg L, Good B. Culture, illness, and care: clinical lessons from anthropologic and cross-cultural research. Ann Intern Med. 1978 Feb;88(2):251–8.
36.
Kleinman A, Benson P. Anthropology in the clinic: the problem of cultural competency and how to fix it. PLoS Med. 2006 Oct;3(10):e294.
37.
Abanades S, Farré M, Segura M, Pichini S, Pastor A, Pacifici R, et al. Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring. Ther Drug Monit. 2007 Feb;29(1):64–70.
38.
Brenneisen R, Elsohly MA, Murphy TP, Passarelli J, Russmann S, Salamone SJ, et al. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol. 2004 Nov-Dec;28(8):625–30.
39.
Kwako LE, Koob GF. Neuroclinical Framework for the Role of Stress in Addiction. Chronic Stress (Thousand Oaks). 2017 Feb;1.
40.
Volkow ND, Koob GF, McLellan AT. Neurobiologic Advances from the Brain Disease Model of Addiction. N Engl J Med. 2016 Jan;374(4):363–71.
41.
Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016 Aug;3(8):760–73.
42.
Koob GF. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction. 2006 Sep;101(Suppl 1):23–30.
43.
Koob GF, Simon EJ. The neurobiology of addiction: where we have been and where we are going. J Drug Issues. 2009 Jan;39(1):115–32.
44.
Bosch OG, Quednow BB, Seifritz E, Wetter TC. Reconsidering GHB: orphan drug or new model antidepressant? J Psychopharmacol. 2012 May;26(5):618–28.
45.
Bosch OG, Seifritz E. The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in humans. Brain Res Bull. 2016 Sep;126(Pt 1):47–60.
46.
McKay JR. Making the hard work of recovery more attractive for those with substance use disorders. Addiction. 2017 May;112(5):751–7.
47.
Schellekens AF, de Jong CA, Buitelaar JK, Verkes RJ. Co-morbid anxiety disorders predict early relapse after inpatient alcohol treatment. Eur Psychiatry. 2015 Jan;30(1):128–36.
48.
McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000 Oct;284(13):1689–95.
49.
Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav. 2012 Jan;37(1):11–24.
50.
Beurmanjer H, Kamal RM, de Jong CA, Dijkstra BA, Schellekens AF. Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial. CNS Drugs. 2018 May;32(5):437–42.
51.
Kamal RM, Loonen AJ, Dijkstra BA, De Jong CA. Baclofen as relapse prevention in the treatment of gamma-hydroxybutyrate dependence: a case series. J Clin Psychopharmacol. 2015 Jun;35(3):313–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.